Eli Lilly announced that EBGLYSS (lebrikizumab-lbkz) demonstrated sustained efficacy in treating moderate-to-severe atopic dermatitis over three years. In the ADjoin long-term extension study, 50% of patients who responded at week 16 achieved complete skin clearance (EASI 100 or IGA 0) after three years with a single monthly maintenance injection, while 87% reached almost-clear skin (EASI 90).

EBGLYSS, an IL-13 inhibitor, was approved in the U.S. in September 2024 as a first-line biologic treatment for patients uncontrolled by topical therapies. Additional studies showed significant improvements in itch, skin pain, and sleep loss due to itching, including among patients with skin of color and those previously treated with dupilumab.

The treatment was well tolerated, with mild-to-moderate adverse events such as conjunctivitis and injection site reactions. Lilly is working to expand insurance coverage and access to EBGLYSS.